Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome
Neuren Pharmaceuticals (ASX:NEU) has said it’s received a “positive” response from the…
Neuren Pharmaceuticals Limited (ASX:NEU)
About Neuren Pharmaceuticals Limited
Key Information
NEU In the News
ASX Announcements
| Date | Announcement | File | Views |
|---|---|---|---|
| 17/10/2024 | Price Sensitive PS DAYBUE receives marketing authorization in Canada | 253.08KB | 17K |
| 07/10/2024 | Price Sensitive PS NEU continues PMS P3 preparations after positive FDA meeting | 211.87KB | 43K |
| 27/08/2024 | H1 2024 financial results | 293.84KB | 8.4K |
| 27/08/2024 | Price Sensitive PS Half Yearly Report and Accounts | 430.01KB | 3.2K |
| 19/08/2024 | Investor roadshow presentation, 19 August 2024 | 1.69MB | 18K |
| 16/08/2024 | Change of Director's Interest Notice - J Basile | 177.9KB | 5.0K |
| 09/08/2024 | NNZ-2591 Angelman top-line results presentation | 2.27MB | 1.1K |
| 09/08/2024 | Price Sensitive PS Phase 2 trial shows significant improvements in Angelman | 499.76KB | 46K |